Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
SomnoMedASX:SOM 43 EV-to-EBIT is -11,555.43 as of Aug. 05, 2026. GuruFocus rates ASX:SOM with a GF Score™ of 43/100 and a GF Value™ of A$0.44 (Fairly Valued). The stock has 3 warning signs investors should review. Among 470 Medical Devices & Instruments companies, SomnoMed ranks worse than 212765.74% on this metric.
EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, SomnoMed's Enterprise Value is A$80.9 Mil.
SomnoMed's EBIT for the trailing twelve months (TTM) ended in Dec. 2025 was A$-0.0 Mil. Therefore, SomnoMed's EV-to-EBIT for today is -11,555.43.
The historical rank and industry rank for SomnoMed's EV-to-EBIT or its related term are showing as below:
ASX:SOM'
s EV-to-EBIT Range Over the Past 10 Years
Min: -13125.15 Med: -9.85 Max: 371.5
Current: -11555.43
During the past 13 years, the highest EV-to-EBIT of SomnoMed was 371.50. The lowest was -13125.15. And the median was -9.85.
ASX:SOM's EV-to-EBIT is ranked worse than 100% of 470
companies
in the Medical Devices & Instruments industry
Industry Median: 19.07
vs ASX:SOM: -11555.43
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
SomnoMed's Enterprise Value for the quarter that ended in Dec. 2025 was A$157.1 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. SomnoMed's EBIT for the trailing twelve months (TTM) ended in Dec. 2025 was A$-0.0 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SomnoMed EV-to-EBIT Related Terms
SomnoMed EV-to-EBIT Historical Data
* Premium members only.
The historical data trend for SomnoMed's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, SomnoMed's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
SomnoMed EV-to-EBIT vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, SomnoMed's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where SomnoMed's EV-to-EBIT falls into.
SomnoMed's current Enterprise Value is A$80.9 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. SomnoMed's EBIT for the trailing twelve months (TTM) ended in Dec. 2025 was A$-0.0 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SomnoMed (ASX:SOM) has a EV-to-EBIT of -11,555.43 as of Aug. 05, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on SomnoMed and its competitors. According to the industry distribution chart, SomnoMed ranks #999999 out of 470 companies in the Medical Devices & Instruments industry.
Is SomnoMed's EV-to-EBIT too high?
SomnoMed's current EV-to-EBIT is -11,555.43. Based on the distribution chart, SomnoMed ranks #999999 out of 470 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, SomnoMed has a GF Score™ of 43/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does SomnoMed's EV-to-EBIT compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, SomnoMed ranks #999999 out of 470 companies for EV-to-EBIT. This places SomnoMed in the lower half of its industry. The industry median EV-to-EBIT is 19.07. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Medical Devices & Instruments company?
The median EV-to-EBIT among Medical Devices & Instruments companies is 19.07, based on 470 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on SomnoMed and its competitors. For the Medical Devices & Instruments industry, the median EV-to-EBIT is 19.07 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. SomnoMed's current EV-to-EBIT is -11,555.43. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is SomnoMed stock overvalued right now?
Based on GuruFocus' analysis, SomnoMed (ASX:SOM) is currently considered Fairly Valued. The stock's GF Value™ is A$0.44, compared to a current price of A$0.42 — trading 4.5% below its estimated fair value. The current EV-to-EBIT is -11,555.43. SomnoMed's overall GF Score™ is 43/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For SomnoMed (ASX:SOM), the current EV-to-EBIT is -11,555.43 as of Aug. 05, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is SomnoMed (ASX:SOM) Overvalued in 2026?
Based on GuruFocus' analysis, SomnoMed stock appears to be undervalued.
The current stock price of A$0.42 is trading 4.5% below its estimated GF Value™ of A$0.44.
GuruFocus considers SomnoMed to be Fairly Valued.
Key valuation signals for ASX:SOM:
EV-to-EBIT: -11,555.43
GF Value™: A$0.44 vs. price of A$0.42 (4.5% below fair value)
No single metric tells the full story. See the ASX:SOM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
SomnoMed Ltd provides treatment solutions for sleep-related breathing disorders, including obstructive sleep apnea, snoring, and bruxism. It is engaged in commercializing SomnoDent Mandibular Advancement Splint (MAS) and other oral devices for sleep-related disorders in Australia and overseas. The other products in the company's portfolio include SomMorning Repositioner; SomnoBrux splint, a custom-fit, acrylic splint (dental guard) for upper teeth designed to protect teeth from grinding and scraping during Bruxism; and SomTabs cleaning tablets that have been developed to clean oral appliances. Geographically, the company generates maximum revenue from Europe, followed by North America and the Asia Pacific region.
43GF Score
Get the complete analysis for ASX:SOM
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:SOM has been successfully added to your 
